OVERVIEW

GHRP‑2 is a synthetic growth hormone-releasing peptide (GHRP) that stimulates the release of endogenous growth hormone (GH) from the anterior pituitary gland. It works primarily by binding to the ghrelin receptor (GHS‑R1a), which triggers pulsatile secretion of GH and subsequently increases insulin-like growth factor‑1 (IGF‑1) levels, a key mediator of many anabolic and regenerative processes. In research settings, GHRP‑2 has been studied for its potential effects on muscle growth, fat metabolism, tissue repair, and overall somatotropic axis regulation. Because it stimulates GH without introducing exogenous hormone, it allows researchers to explore natural hormone signaling, pituitary function, and downstream metabolic pathways. GHRP‑2 has also been evaluated in preclinical models for potential roles in recovery from injury, improving lean body mass, and modulating energy metabolism.

Despite its research applications, GHRP‑2 is not approved by the U.S. Food and Drug Administration for therapeutic use in humans. Most available data come from animal studies, in vitro experiments, or small clinical trials, and long-term safety, optimal dosing, and efficacy in humans remain largely unestablished. Products containing GHRP‑2 are typically labeled for research use only and are not regulated to pharmaceutical-grade standards, so purity and potency may vary. Self-administration outside controlled research environments carries potential health, ethical, and legal risks. Individuals interested in growth hormone therapies or metabolic support should rely on evidence-based treatments and consult qualified healthcare professionals rather than unapproved peptides.